

David P Nicolau

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4381899/david-p-nicolau-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

367
papers

6,587
citations

41
h-index

62
g-index

391
ext. papers

8,023
ext. citations

5
avg, IF

6.85
L-index

#	Paper	IF	Citations
367	In vitro Time Kill of Trimethoprim/Sulfamethoxazole against versus using Cation Adjusted Muller Hinton Broth and ISO-Sensitest Broth.. <i>Antimicrobial Agents and Chemotherapy</i> , 2022 , aac0216721	5.9	1
366	Minocycline pharmacodynamics against <i>Stenotrophomonas maltophilia</i> in the neutropenic murine infection model: implications for susceptibility breakpoints.. <i>Journal of Antimicrobial Chemotherapy</i> , 2022 ,	5.1	1
365	Ceftolozane/tazobactam for refractory <i>P. aeruginosa</i> endocarditis: A case report and pharmacokinetic analysis. <i>Journal of Infection and Chemotherapy</i> , 2022 , 28, 87-90	2.2	1
364	Murine Model for Measuring Effects of Humanized-Dosing of Antibiotics on the Gut Microbiome.. <i>Frontiers in Microbiology</i> , 2022 , 13, 813849	5.7	
363	Carbapenemase-producing -an emerging challenge.. <i>Emerging Microbes and Infections</i> , 2022 , 11, 811-814	18.9	2
362	Comparison of Zinc Concentrations in the Broth of Commercial Automated Susceptibility Testing Devices (Vitek 2, MicroScan, BD Phoenix, and Sensititre).. <i>Microbiology Spectrum</i> , 2022 , e0005222	8.9	1
361	Multicenter, Prospective Validation of a Phenotypic Algorithm to Guide Carbapenemase Testing in Carbapenem-Resistant Using the ERACE-PA Global Surveillance Program.. <i>Open Forum Infectious Diseases</i> , 2022 , 9, ofab617	1	1
360	Assessment of sustained efficacy and resistance emergence under human-simulated exposure of cefiderocol against using chemostat and murine infection models.. <i>JAC-Antimicrobial Resistance</i> , 2022 , 4, dlac047	2.9	
359	In vitro potency of amikacin against carbapenem-resistant <i>Pseudomonas aeruginosa</i> : A target for nebulization strategy?. <i>Brazilian Journal of Infectious Diseases</i> , 2022 , 26, 102355	2.8	
358	Pharmacokinetics and Time above the MIC Exposure of Cefepime in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation (ECMO).. <i>International Journal of Antimicrobial Agents</i> , 2022 , 106603	14.3	0
357	1103. Minocycline (MIN) Pharmacodynamics (PD) against <i>Stenotrophomonas maltophilia</i> (STM) in a Neutropenic Murine Thigh Infection Model. <i>Open Forum Infectious Diseases</i> , 2021 , 8, S643-S643	1	
356	Evaluation of Metallo- β -Lactamase Susceptibility Testing in a Physiologic Medium. <i>Microbiology Spectrum</i> , 2021 , e0167021	8.9	0
355	Clinical exposure-response relationship of cefepime/taniborbactam against Gram-negative organisms in the murine complicated urinary tract infection model. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 ,	5.1	3
354	Development and characterization of a new swine model of invasive pneumococcal pneumonia. <i>Lab Animal</i> , 2021 , 50, 327-335	0.4	
353	Activity of WCK 4282 (High-Dose Cefepime/Tazobactam) against Serine- β -Lactamase-Producing and <i>Pseudomonas aeruginosa</i> in the Neutropenic Murine Lung Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2021 , 65,	5.9	2
352	Pharmacokinetics and Pharmacodynamics of Ceftolozane/Tazobactam in Critically Ill Patients With Augmented Renal Clearance. <i>International Journal of Antimicrobial Agents</i> , 2021 , 57, 106299	14.3	10
351	Activity of β -Lactam Antibiotics against Metallo- β -Lactamase-Producing in Animal Infection Models: a Current State of Affairs. <i>Antimicrobial Agents and Chemotherapy</i> , 2021 , 65,	5.9	9

350	Cefiderocol Pharmacokinetics in a Patient Receiving Continuous Venovenous Hemodiafiltration. <i>Open Forum Infectious Diseases</i> , 2021 , 8, ofab252	1	1
349	A Novel Dosing Strategy of Ceftolozane/Tazobactam in a Patient Receiving Intermittent Hemodialysis. <i>Open Forum Infectious Diseases</i> , 2021 , 8, ofab238	1	0
348	In vitro synergy of ticarcillin/clavulanate in combination with aztreonam and ceftolozane/tazobactam against SPM-1-producing <i>Pseudomonas aeruginosa</i> strains. <i>Diagnostic Microbiology and Infectious Disease</i> , 2021 , 100, 115343	2.9	0
347	Comment on: An update on cefepime and its future role in combination with novel β -lactamase inhibitors for MDR Enterobacterales and <i>Pseudomonas aeruginosa</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2021 , 76, 3326-3327	5.1	1
346	Comparative in vivo activity of human-simulated plasma and epithelial lining fluid exposures of WCK 5222 (cefepime/zidebactam) against KPC- and OXA-48-like-producing <i>Klebsiella pneumoniae</i> in the neutropenic murine pneumonia model. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 , 76, 2310-2316	5.1	2
345	Discrepancy in sustained efficacy and resistance emergence under human-simulated exposure of cefiderocol against <i>Stenotrophomonas maltophilia</i> between in vitro chemostat and in vivo murine infection models. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 , 76, 2615-2621	5.1	5
344	Evaluation of Linezolid Pharmacokinetics in Critically Ill Obese Patients with Severe Skin and Soft Tissue Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2021 , 65,	5.9	4
343	The paradoxical in vivo activity of β -lactams against metallo- β -lactamase-producing Enterobacterales is not restricted to carbapenems. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 , 76, 684-691	5.1	8
342	The Ongoing Challenge with NDM-Harboring in Murine Infection Models. <i>Antimicrobial Agents and Chemotherapy</i> , 2021 , 65,	5.9	1
341	Bactericidal In Vitro Activity of a Tissue-Achievable Concentration of Cefazolin against Methicillin-Resistant. <i>Surgical Infections</i> , 2021 , 22, 447-449	2	
340	Efficacy of human-simulated exposures of meropenem/vaborbactam and meropenem against OXA-48 β -lactamase-producing Enterobacterales in the neutropenic murine thigh infection model. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 , 76, 184-188	5.1	2
339	Contemporary analysis of ETEST for antibiotic susceptibility and minimum inhibitory concentration agreement against <i>Pseudomonas aeruginosa</i> from patients with cystic fibrosis. <i>Annals of Clinical Microbiology and Antimicrobials</i> , 2021 , 20, 9	6.2	4
338	A guide to therapeutic drug monitoring of β -lactam antibiotics. <i>Pharmacotherapy</i> , 2021 , 41, 220-233	5.8	15
337	Pharmacodynamics of Ceftibuten: An Assessment of an Oral Cephalosporin against Enterobacterales in a Neutropenic Murine Thigh Model. <i>Antibiotics</i> , 2021 , 10,	4.9	1
336	The ERACE-PA Global Surveillance Program: Ceftolozane/tazobactam and Ceftazidime/avibactam in vitro Activity against a Global Collection of Carbapenem-resistant <i>Pseudomonas aeruginosa</i> . <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021 , 40, 2533-2541	5.3	13
335	Efficacy assessment of lysin CF-296 in addition to daptomycin or vancomycin against <i>Staphylococcus aureus</i> in the murine thigh infection model. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 , 76, 2622-2628	5.1	1
334	Pharmacokinetics, Tissue Distribution, and Efficacy of VIO-001 (Meropenem/Piperacillin/Tazobactam) for Treatment of Methicillin-Resistant <i>Staphylococcus aureus</i> Bacteremia in Immunocompetent Rabbits with Chronic Indwelling Vascular Catheters. <i>Antimicrobial Agents and Chemotherapy</i> , 2021 , 65, e0116821	5.9	0
333	Intrapulmonary pharmacokinetic profile of cefiderocol in mechanically ventilated patients with pneumonia. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 , 76, 2902-2905	5.1	7

332	Reply to Rennie, "Zinc Concentration Affects Metallo-Beta-Lactamase Susceptibility Testing of". <i>Journal of Clinical Microbiology</i> , 2021 , 59, e0121121	9.7	1
331	Elevated MICs of Susceptible Antipseudomonal Cephalosporins in Non-Carbapenemase-Producing, Carbapenem-Resistant <i>Pseudomonas aeruginosa</i> : Implications for Dose Optimization. <i>Antimicrobial Agents and Chemotherapy</i> , 2021 , 65, e0120421	5.9	1
330	Evaluation of a Phenotypic Algorithm to Direct Carbapenemase Testing in : Validation in a Multicenter German Cohort. <i>Microbial Drug Resistance</i> , 2021 , 27, 1243-1248	2.9	3
329	Phenotypic/Genotypic Profile of OXA-10-Like-Harboring, Carbapenem-Resistant <i>Pseudomonas aeruginosa</i> : Using Validated Pharmacokinetic/Pharmacodynamic Models To Further Evaluate Enzyme Functionality and Clinical Implications. <i>Antimicrobial Agents and Chemotherapy</i> , 2021 , 65, e0127421	5.9	1
328	Optimised cefiderocol exposures in a successfully treated critically ill patient with polymicrobial <i>Stenotrophomonas maltophilia</i> bacteraemia and pneumonia receiving continuous venovenous haemodiafiltration. <i>International Journal of Antimicrobial Agents</i> , 2021 , 58, 106395	14.3	3
327	In vivo activity of WCK 4282 (high-dose cefepime/tazobactam) against serine β -lactamase-producing Enterobacterales and <i>Pseudomonas aeruginosa</i> in the neutropenic murine thigh infection model. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 , 76, 993-1000	5.1	1
326	1109. Pharmacokinetics and Exposure of Cefepime in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation (ECMO). <i>Open Forum Infectious Diseases</i> , 2021 , 8, S646-S646	1	
325	58. Impact of Order-set Modifications and Provider Education on Broad-Spectrum Antibiotic Use in Patients Admitted with Community Acquired Pneumonia. <i>Open Forum Infectious Diseases</i> , 2021 , 8, S147-S148		
324	1087. Imipenem-Cilastatin-Relebactam (I/R) Pharmacokinetics (PK) in Critically Ill Patients with Augmented Renal Clearance (ARC). <i>Open Forum Infectious Diseases</i> , 2021 , 8, S635-S635	1	0
323	65. In Vivo Efficacy of Human Simulated Minocycline (MIN) against <i>Stenotrophomonas maltophilia</i> (STM). <i>Open Forum Infectious Diseases</i> , 2021 , 8, S44-S44	1	
322	1241. In Vivo Efficacy of Meropenem Against Metallo- β -Lactamase (MBL)-Harboring <i>Pseudomonas aeruginosa</i> and Correlation to In Vitro Susceptibility Upon Addition of EDTA. <i>Open Forum Infectious Diseases</i> , 2021 , 8, S710-S710	1	
321	Evaluation of high-concentration EDTA-modified carbapenemase inactivation method (eCIM) for SPM-producing <i>Pseudomonas aeruginosa</i> .. <i>Archives of Microbiology</i> , 2021 , 204, 55	3	
320	Efficacy of human-simulated bronchopulmonary exposures of cefepime, zidebactam and the combination (WCK 5222) against MDR <i>Pseudomonas aeruginosa</i> in a neutropenic murine pneumonia model. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 149-155	5.1	16
319	Development of Daptomycin Susceptibility Breakpoints for <i>Enterococcus faecium</i> and Revision of the Breakpoints for Other Enterococcal Species by the Clinical and Laboratory Standards Institute. <i>Clinical Infectious Diseases</i> , 2020 , 70, 1240-1246	11.6	15
318	Precision medicine for the diagnosis and treatment of carbapenem-resistant Enterobacterales: time to think from a different perspective. <i>Expert Review of Anti-Infective Therapy</i> , 2020 , 18, 721-740	5.5	2
317	In vivo activity of human-simulated regimens of imipenem alone and in combination with relebactam against <i>Pseudomonas aeruginosa</i> in the murine thigh infection model. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 2197-2205	5.1	5
316	Assessment of Meropenem and Vaborbactam Room Temperature and Refrigerated Stability in Polyvinyl Chloride Bags and Elastomeric Devices. <i>Clinical Therapeutics</i> , 2020 , 42, 606-613	3.5	1
315	Clinical pharmacokinetics of ceftolozane and tazobactam in an obese patient receiving continuous venovenous haemodiafiltration: A patient case and literature review. <i>Journal of Global Antimicrobial Resistance</i> , 2020 , 21, 83-85	3.4	6

314	Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumonia. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 1546-1553	5.1	24
313	Carbapenem-Resistant Enterobacterales, Carbapenem Resistant Organisms, Carbapenemase-Producing Enterobacterales, and Carbapenemase-Producing Organisms: Terminology Past its "Sell-By Date" in an Era of New Antibiotics and Regional Carbapenemase Epidemiology. <i>Clinical Infectious Diseases</i> , 2020 , 71, 1776-1782	11.6	24
312	Carbapenem-Resistant Enterobacterales: Considerations for Treatment in the Era of New Antimicrobials and Evolving Enzymology. <i>Current Infectious Disease Reports</i> , 2020 , 22, 6	3.9	23
311	Metallo- β -lactamase resistance in Enterobacteriaceae is an artefact of currently utilized antimicrobial susceptibility testing methods. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 997-1005	5.1	25
310	Pharmacodynamic comparison of different antimicrobial regimens against Staphylococcus aureus bloodstream infections with elevated vancomycin minimum inhibitory concentration. <i>BMC Infectious Diseases</i> , 2020 , 20, 74	4	1
309	Comparative Evaluation of the Activities of WCK 5222 (Cefepime-Zidebactam) and Combination Antibiotic Therapies against Carbapenem-Resistant. <i>Antimicrobial Agents and Chemotherapy</i> , 2020 , 64,	5.9	12
308	In vitro synergy of ceftolozane/tazobactam in combination with fosfomycin or aztreonam against MDR Pseudomonas aeruginosa. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 1874-1878	5.1	15
307	Evaluation of the EDTA-Modified Carbapenem Inactivation Method for Detecting Metallo- β -lactamase-Producing. <i>Journal of Clinical Microbiology</i> , 2020 , 58,	9.7	26
306	Falsely elevated vancomycin-concentration values from enzyme immunoassay leading to treatment failure. <i>American Journal of Health-System Pharmacy</i> , 2020 , 77, 9-13	2.2	1
305	1317. Pharmacokinetics (PK) of Ampicillin-Sulbactam (SAM) during Orthotopic Liver Transplantation (OLT). <i>Open Forum Infectious Diseases</i> , 2020 , 7, S670-S670	1	0
304	Human-Simulated Antimicrobial Regimens in Animal Models: Transparency and Validation Are Imperative. <i>Antimicrobial Agents and Chemotherapy</i> , 2020 , 64,	5.9	4
303	1264. Assessment of In Vivo Efficacy of CF-296 in addition to Vancomycin (VAN) and Daptomycin (DAP) against Staphylococcus aureus in the Neutropenic Murine Thigh Infection Model. <i>Open Forum Infectious Diseases</i> , 2020 , 7, S648-S649	1	
302	1308. Ex vivo Impact of Autologous Blood Transfusion (ABT) on Concentrations of Antibiotics used for Surgical Prophylaxis. <i>Open Forum Infectious Diseases</i> , 2020 , 7, S667-S667	1	
301	1245. In Vivo Efficacy of WCK 4282 (High Dose Cefepime [FEP]-Tazobactam [TZB]) Against β -lactamase-Producing (BLP) Gram-Negative Bacteria in a Neutropenic Murine Pneumonia Model. <i>Open Forum Infectious Diseases</i> , 2020 , 7, S641-S641	1	
300	13. Evaluation of Etest for Antibiotic Susceptibility and Minimum Inhibitory Concentration (MIC) Agreement Against pseudomonas Aeruginosa (psa) from Patients with Cystic Fibrosis (CF). <i>Open Forum Infectious Diseases</i> , 2020 , 7, S7-S8	1	
299	656. Development and Application of a Pragmatic Algorithm for the Detection of Carbapenemase-Producing Pseudomonas aeruginosa (CP-PA). <i>Open Forum Infectious Diseases</i> , 2020 , 7, S384-S385	1	
298	1312. Metallo- β -lactamase-Producing Enterobacterales (MBL-EB): Is it Time to Rethink Our Assessment Tools?. <i>Open Forum Infectious Diseases</i> , 2020 , 7, S668-S668	1	
297	1602. Comparative Activity of Ceftolozane-Tazobactam (C/T) and Ceftazidime-Avibactam (CZA) against Pseudomonas aeruginosa (PSA) from Patients with Cystic Fibrosis (CF). <i>Open Forum Infectious Diseases</i> , 2020 , 7, S797-S797	1	

296	1244. Assessment of the In Vivo Activity of Human-Simulated Exposure of WCK 4282 (High Dose Cefepime [FEP]-Tazobactam [TZB]) against Enterobacterales (EB) and Pseudomonas aeruginosa (PA) in the Neutropenic Murine Thigh Infection Model. <i>Open Forum Infectious Diseases</i> , 2020 , 7, S640-S641	1	
295	1309. Imipenem/Cilastatin/Relebactam (I/R) Alone and in Combination against Pseudomonas aeruginosa (PSA) in the In Vitro Pharmacodynamic Model. <i>Open Forum Infectious Diseases</i> , 2020 , 7, S667-S667	1	
294	1299. In Vitro-In Vivo Discordance with β -lactams against Metallo- β -lactamase-Producing Enterobacterales: Implications for Susceptibility Testing. <i>Open Forum Infectious Diseases</i> , 2020 , 7, S664-S664	1	
293	1215. Evaluation of the Carba-R NxG Assay in a Global Challenge Set of Pseudomonas aeruginosa. <i>Open Forum Infectious Diseases</i> , 2020 , 7, S629-S629	1	
292	1296. Efficacy of Human-Simulated Exposures of Meropenem/Vaborbactam (MVB) and Meropenem (MEM) against OXA-48 β -lactamase-producing Enterobacterales in the Neutropenic Murine Thigh Infection Model. <i>Open Forum Infectious Diseases</i> , 2020 , 7, S663-S663	1	
291	1302. Cefiderocol Population Pharmacokinetics and Probability of Target Attainment in Plasma and Epithelial Lining Fluid in Patients with Pneumonia, Bloodstream Infection/Sepsis, or Complicated Urinary Tract Infections. <i>Open Forum Infectious Diseases</i> , 2020 , 7, S665-S665	1	4
290	1311. Intrapulmonary Pharmacokinetics of Cefiderocol in Hospitalized and Ventilated Patients Receiving Standard of Care Antibiotics for Bacterial Pneumonia. <i>Open Forum Infectious Diseases</i> , 2020 , 7, S668-S668	1	3
289	Efficacy and Safety of Eravacycline in Obese Patients: A Post Hoc Analysis of Pooled Data From the IGNITE1 and IGNITE4 Clinical Trials. <i>Open Forum Infectious Diseases</i> , 2020 , 7, ofaa548	1	1
288	Meropenem-nacubactam activity against AmpC-overproducing and KPC-expressing Pseudomonas aeruginosa in a neutropenic murine lung infection model. <i>International Journal of Antimicrobial Agents</i> , 2020 , 55, 105838	14.3	13
287	Monte Carlo Simulation Methodologies for β -lactam/ β -lactamase Inhibitor Combinations: Effect on Probability of Target Attainment Assessments. <i>Journal of Clinical Pharmacology</i> , 2020 , 60, 172-180	2.9	5
286	Piperacillin-Tazobactam-Resistant/Third-Generation Cephalosporin-Susceptible Escherichia coli and Klebsiella pneumoniae Isolates: Resistance Mechanisms and In vitro-In vivo Discordance. <i>International Journal of Antimicrobial Agents</i> , 2020 , 55, 105885	14.3	8
285	Evaluation of the in vitro activity of WCK 5222 (cefepime/zidebactam) and currently available combination therapies against single- and double-carbapenemase producing Enterobacteriaceae: Expanding the zone of hope. <i>International Journal of Antimicrobial Agents</i> , 2020 , 55, 105863	14.3	10
284	Inhaled amikacin adjunctive to intravenous standard-of-care antibiotics in mechanically ventilated patients with Gram-negative pneumonia (INHALE): a double-blind, randomised, placebo-controlled, phase 3, superiority trial. <i>Lancet Infectious Diseases</i> , 2020 , 20, 330-340	25.5	38
283	Diagnostic and medical needs for therapeutic drug monitoring of antibiotics. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2020 , 39, 791-797	5.3	28
282	Synergistic Activity of Exebacase (CF-301) in Addition to Daptomycin against Staphylococcus aureus in a Neutropenic Murine Thigh Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2020 , 64,	5.9	9
281	Variability in Zinc Concentration among Mueller-Hinton Broth Brands: Impact on Antimicrobial Susceptibility Testing of Metallo- β -lactamase-Producing. <i>Journal of Clinical Microbiology</i> , 2020 , 58,	9.7	11
280	Use of continuous-infusion ceftolozane/tazobactam for resistant Gram-negative bacterial infections: a retrospective analysis and brief review of the literature. <i>International Journal of Antimicrobial Agents</i> , 2020 , 56, 106158	14.3	9
279	Augmented Renal Clearance and How to Augment Antibiotic Dosing. <i>Antibiotics</i> , 2020 , 9,	4.9	17

278	Impact of Intraoperative Cell Salvage on Concentrations of Antibiotics Used for Surgical Prophylaxis. <i>Antimicrobial Agents and Chemotherapy</i> , 2020 , 64,	5.9	1
277	EDTA-modified carbapenem inactivation method (eCIM) for detecting IMP Metallo- β -lactamase-producing <i>Pseudomonas aeruginosa</i> : an assessment of increasing EDTA concentrations. <i>BMC Microbiology</i> , 2020 , 20, 220	4.5	5
276	Development of an HPLC Method for the Determination of Meropenem/Vaborbactam in Biological and Aqueous Matrixes. <i>Journal of Chromatographic Science</i> , 2020 , 58, 726-730	1.4	3
275	Imipenem/Cilastatin/Relebactam Alone and in Combination against in the Pharmacodynamic Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2020 , 64,	5.9	2
274	Evaluation of the Xpert Carba-R NxG Assay for Detection of Carbapenemase Genes in a Global Challenge Set of <i>Pseudomonas aeruginosa</i> Isolates. <i>Journal of Clinical Microbiology</i> , 2020 , 58,	9.7	6
273	Development and Application of a Pragmatic Algorithm to Guide Definitive Carbapenemase Testing to Identify Carbapenemase-Producing. <i>Antibiotics</i> , 2020 , 9,	4.9	7
272	In vivo pharmacodynamics of new-generation β -lactamase inhibitor taniborbactam (formerly VNRX-5133) in combination with cefepime against serine- β -lactamase-producing Gram-negative bacteria. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 3601-3610	5.1	10
271	Single β -lactams versus combinations as empiric therapy for infections with : assessing the susceptibility. <i>Infectious Diseases</i> , 2020 , 52, 33-38	3.1	2
270	Critique of prevention of pneumococcal disease in high risk adults: A pharmacist-based assessment of adult immunization protocols in clinical practice. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2019 , 2, 444-445	1.4	
269	Effect of Clinically Meaningful Antibiotic Concentrations on Recovery of <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> Isolates from Anaerobic Blood Culture Bottles with and without Antibiotic Binding Resins. <i>Journal of Clinical Microbiology</i> , 2019 , 57,	9.7	5
268	Efficacy of Human-Simulated Epithelial Lining Fluid Exposure of Meropenem-Nacubactam Combination against Class A Serine β -Lactamase-Producing in the Neutropenic Murine Lung Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	12
267	In vitro investigation of synergy among fosfomycin and parenteral antimicrobials against carbapenemase-producing Enterobacteriaceae. <i>Diagnostic Microbiology and Infectious Disease</i> , 2019 , 95, 216-220	2.9	5
266	Carbapenem-Nonsusceptible Isolates from Intensive Care Units in the United States: a Potential Role for New β -Lactam Combination Agents. <i>Journal of Clinical Microbiology</i> , 2019 , 57,	9.7	21
265	Pharmacodynamic Profile of Ceftibuten-Clavulanate Combination against Extended-Spectrum- β -Lactamase-Producing Enterobacteriaceae in the Murine Thigh Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	13
264	Pharmacodynamics of a Novel Ceftibuten-Clavulanate Combination Antibiotic against Enterobacteriaceae. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	7
263	In vitro activity of ampicillin and ceftriaxone against ampicillin-susceptible <i>Enterococcus faecium</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 2269-2273	5.1	11
262	Where should antibiotic gradient diffusion strips be crossed to assess synergy? A comparison of the standard method with a novel method using steady-state antimicrobial concentrations. <i>International Journal of Antimicrobial Agents</i> , 2019 , 53, 698-702	14.3	2
261	Reply to Cheng and Chuang. <i>Clinical Infectious Diseases</i> , 2019 , 69, 903-904	11.6	0

260	Use of continuous infusion ceftolozane-tazobactam with therapeutic drug monitoring in a patient with cystic fibrosis. <i>American Journal of Health-System Pharmacy</i> , 2019 , 76, 501-504	2.2	14
259	Development of an HPLC-MS/MS method for the determination of ceftolozane/tazobactam in bronchoalveolar lavage fluid. <i>Future Science OA</i> , 2019 , 5, FSO352	2.7	3
258	potency of antipseudomonal β lactams against blood and respiratory isolates of collected from US hospitals. <i>Journal of Thoracic Disease</i> , 2019 , 11, 1896-1902	2.6	7
257	Pharmacokinetics-pharmacodynamics of β lactamase inhibitors: are we missing the target?. <i>Expert Review of Anti-Infective Therapy</i> , 2019 , 17, 571-582	5.5	12
256	Application of the Hartford Hospital Nomogram for Plazomicin Dosing Interval Selection in Patients with Complicated Urinary Tract Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	5
255	Recovery of Gram-Negative Bacteria from Aerobic Blood Culture Bottles Containing Antibiotic Binding Resins after Exposure to β Lactam and Fluoroquinolone Concentrations. <i>Journal of Clinical Microbiology</i> , 2019 , 57,	9.7	4
254	Comparative efficacy of linezolid and vancomycin for endotracheal tube MRSA biofilms from ICU patients. <i>Critical Care</i> , 2019 , 23, 251	10.8	9
253	A Simulated Application of the Hartford Hospital Aminoglycoside Dosing Nomogram for Plazomicin Dosing Interval Selection in Patients With Serious Infections Caused by Carbapenem-Resistant Enterobacterales. <i>Clinical Therapeutics</i> , 2019 , 41, 1453-1462	3.5	7
252	Ceftolozane-Tazobactam in the Treatment of Experimental <i>Pseudomonas aeruginosa</i> Pneumonia in Persistently Neutropenic Rabbits: Impact on Strains with Genetically Defined Mechanisms of Resistance. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	7
251	Evaluation of Plazomicin, Tigecycline, and Meropenem Pharmacodynamic Exposure against Carbapenem-Resistant Enterobacteriaceae in Patients with Bloodstream Infection or Hospital-Acquired/Ventilator-Associated Pneumonia from the CARE Study (ACHN-490-007). <i>Infectious Diseases and Therapy</i> , 2019 , 6, 363-366	6.2	8
250	Efficacy of WCK 5222 (Cefepime-Zidebactam) against Multidrug-Resistant in the Neutropenic Murine Thigh Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	21
249	Activity of Imipenem-Relebactam Alone or in Combination with Amikacin or Colistin against <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	13
248	Pharmacodynamics of daptomycin in combination with other antibiotics for the treatment of enterococcal bacteraemia. <i>International Journal of Antimicrobial Agents</i> , 2019 , 54, 346-350	14.3	5
247	Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration. <i>Clinical Therapeutics</i> , 2019 , 41, 2162-2170	3.5	1
246	1544. Efficacy of Human-Simulated Cefiderocol Exposure Against Gram-Negative Bacteria in an Iron-Overloaded Murine Thigh Infection Model. <i>Open Forum Infectious Diseases</i> , 2019 , 6, S563-S563	1	78
245	Prevalence of in vitro synergistic antibiotic interaction between fosfomycin and nonsusceptible antimicrobials in carbapenem-resistant <i>Pseudomonas aeruginosa</i> . <i>Journal of Medical Microbiology</i> , 2019 , 68, 893-897	3.2	11
244	1533. Is Cation-Adjusted Mueller-Hinton Broth (CAMHB) Appropriate for Metallo- β lactamase (MBL) Susceptibility Testing? Novel Insights in In Vitro-In Vivo Discordance Among MBL-Producing Enterobacteriaceae. <i>Open Forum Infectious Diseases</i> , 2019 , 6, S558-S559	1	78
243	682. In Vivo Pharmacodynamics of VNRX-7145 in the Neutropenic Murine Thigh Infection Model When Administered in Combination with Humanized Exposures of Twice Daily Ceftibuten (CTB) Against Serine β Lactamase-Producing Enterobacteriaceae (SBL-EB). <i>Open Forum Infectious Diseases</i> , 2019 , 6, S311-S311	1	2

242	675. Efficacy of Human-Simulated Bronchopulmonary Exposures of Cefepime and Zidebactam (WCK 5222) Against Multidrug-Resistant (MDR) <i>Pseudomonas aeruginosa</i> (PSA) in a Neutropenic Murine Pneumonia Model. <i>Open Forum Infectious Diseases</i> , 2019 , 6, S308-S308	1	78
241	725. WCK 5222 (Cefepime/Zidebactam): An In Vitro Assessment of Activity Compared with Current Dual-Antibiotic Options Against Multidrug-Resistant <i>Pseudomonas aeruginosa</i> . <i>Open Forum Infectious Diseases</i> , 2019 , 6, S325-S325	1	78
240	1550. PK-PD Relationship and PK Driver of Efficacy of the Novel Antibacterial Lysin Exebacase (CF-301) in Pre-Clinical Models. <i>Open Forum Infectious Diseases</i> , 2019 , 6, S565-S566	1	1
239	1553. Human-Simulated Pharmacokinetic Profiles of Cefiderocol and Meropenem Are Conserved in Murine Models of Thigh Infection With or Without Iron Overload. <i>Open Forum Infectious Diseases</i> , 2019 , 6, S567-S567	1	78
238	685. An In Vitro Investigation of WCK 5222 (Cefepime/Zidebactam) and Currently Available Combination Antibiotic Regimens Against Enterobacteriaceae That Co-express Serine- β -Lactamase (SBL) and Metallo- β -Lactamase (MBL) Enzymes. <i>Open Forum Infectious Diseases</i> , 2019 , 6, S311-S312	1	78
237	Pharmacokinetics of Telavancin in Adult Patients with Cystic Fibrosis during Acute Pulmonary Exacerbation. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 64,	5.9	4
236	450. Evaluation of Linezolid Pharmacokinetics in Obese Patients with Severe Skin and Soft-Tissue Infections. <i>Open Forum Infectious Diseases</i> , 2019 , 6, S221-S221	1	78
235	Comparative Antibacterial Activity of Human-Simulated Exposures of Cefiderocol and Ceftazidime against in the Murine Thigh Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 ,	5.9	20
234	Efficacy of Humanized Cefiderocol Exposure Is Unaltered by Host Iron Overload in the Thigh Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 64,	5.9	11
233	Development of Neutropenic Murine Models of Iron Overload and Depletion To Study the Efficacy of Siderophore-Antibiotic Conjugates. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 64,	5.9	9
232	Pharmacokinetics of Cefazolin and Vancomycin in Infants Undergoing Open-Heart Surgery With Cardiopulmonary Bypass. <i>Anesthesia and Analgesia</i> , 2019 , 128, 935-943	3.9	5
231	Nebulized Amikacin and Fosfomycin for Severe <i>Pseudomonas aeruginosa</i> Pneumonia: An Experimental Study. <i>Critical Care Medicine</i> , 2019 , 47, e470-e477	1.4	7
230	Pharmacodynamic Analysis of Daptomycin-treated Enterococcal Bacteremia: It Is Time to Change the Breakpoint. <i>Clinical Infectious Diseases</i> , 2019 , 68, 1650-1657	11.6	22
229	Comparative efficacy of human-simulated epithelial lining fluid exposures of tedizolid, linezolid and vancomycin in neutropenic and immunocompetent murine models of staphylococcal pneumonia. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 970-977	5.1	5
228	Pharmacokinetic and Pharmacodynamic Analysis of Ceftazidime/Avibactam in Critically Ill Patients. <i>Surgical Infections</i> , 2019 , 20, 55-61	2	22
227	Efficacy of Humanized WCK 5222 (Cefepime-Zidebactam) Exposures against Carbapenem-Resistant <i>Acinetobacter baumannii</i> in the Neutropenic Thigh Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	21
226	Is One Sample Enough? β -Lactam Target Attainment and Penetration into Epithelial Lining Fluid Based on Multiple Bronchoalveolar Lavage Sampling Time Points in a Swine Pneumonia Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	4
225	Efficacy of Humanized Cefiderocol Exposures over 72 Hours against a Diverse Group of Gram-Negative Isolates in the Neutropenic Murine Thigh Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	17

224	Humanized Exposures of Cefiderocol, a Siderophore Cephalosporin, Display Sustained in vivo Activity against Siderophore-Resistant <i>Pseudomonas aeruginosa</i> . <i>Pharmacology</i> , 2018 , 101, 278-284	2.3	26
223	Efficacy of Human-Simulated Exposures of Ceftolozane-Tazobactam Alone and in Combination with Amikacin or Colistin against Multidrug-Resistant <i>Pseudomonas aeruginosa</i> in an Pharmacodynamic Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	17
222	Meropenem time above the MIC exposure is predictive of response in cystic fibrosis children with acute pulmonary exacerbations. <i>Diagnostic Microbiology and Infectious Disease</i> , 2018 , 91, 294-297	2.9	10
221	Investigational drugs for the treatment of infections caused by multidrug-resistant Gram-negative bacteria. <i>Expert Opinion on Investigational Drugs</i> , 2018 , 27, 325-338	5.9	23
220	Assessment of in vivo efficacy of eravacycline against Enterobacteriaceae exhibiting various resistance mechanisms: a dose-ranging study and pharmacokinetic/pharmacodynamic analysis. <i>International Journal of Antimicrobial Agents</i> , 2018 , 51, 727-732	14.3	14
219	Novel pharmacotherapy for the treatment of hospital-acquired and ventilator-associated pneumonia caused by resistant gram-negative bacteria. <i>Expert Opinion on Pharmacotherapy</i> , 2018 , 19, 397-408	4	15
218	Subcutaneous cefazolin to reduce surgical site infections in a porcine model. <i>Journal of Surgical Research</i> , 2018 , 224, 156-159	2.5	2
217	Antibacterial activity of ceftolozane/tazobactam alone and in combination with other antimicrobial agents against MDR <i>Pseudomonas aeruginosa</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 942-952	5.1	28
216	Physical Compatibility of Meropenem and Vaborbactam With Select Intravenous Drugs During Simulated Y-site Administration. <i>Clinical Therapeutics</i> , 2018 , 40, 261-269	3.5	10
215	Humanized Exposures of a β -Lactam- β -Lactamase Inhibitor, Tazobactam, versus Non- β -Lactam- β -Lactamase Inhibitor, Avibactam, with or without Colistin, against <i>Acinetobacter baumannii</i> in Murine Thigh and Lung Infection Models. <i>Pharmacology</i> , 2018 , 101, 255-261	2.3	4
214	Pharmacodynamics of cefiderocol, a novel siderophore cephalosporin, in a <i>Pseudomonas aeruginosa</i> neutropenic murine thigh model. <i>International Journal of Antimicrobial Agents</i> , 2018 , 51, 206-212	14.3	33
213	Antibacterial Activity of Human Simulated Epithelial Lining Fluid Concentrations of Ceftazidime-Avibactam Alone or in Combination with Amikacin Inhale (BAY41-6551) against Carbapenem-Resistant <i>Pseudomonas aeruginosa</i> and <i>Klebsiella pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	9
212	Review of antimicrobial use and considerations in the elderly population. <i>Clinical Interventions in Aging</i> , 2018 , 13, 657-667	4	24
211	Efficacy of Meropenem with a Novel Non- β -Lactam- β -Lactamase Inhibitor, Nacubactam, against Gram-Negative Organisms Exhibiting Various Resistance Mechanisms in a Murine Complicated Urinary Tract Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	30
210	Management of Pediatric Acute Hematogenous Osteomyelitis, Part II: A Focus on Methicillin-Resistant <i>Staphylococcus aureus</i> , Current and Emerging Therapies. <i>Pharmacotherapy</i> , 2018 , 38, 1021-1037	5.8	9
209	Pharmacodynamics of Daptomycin against <i>Enterococcus faecium</i> and <i>Enterococcus faecalis</i> in the Murine Thigh Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	12
208	Assessing the in vitro activity of ceftazidime/avibactam and aztreonam among carbapenemase-producing Enterobacteriaceae: Defining the zone of hope. <i>International Journal of Antimicrobial Agents</i> , 2018 , 52, 688-691	14.3	23
207	Feasibility of routine synergy testing using antibiotic gradient diffusion strips in the clinical laboratory. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 2264-2265	5.1	6

206	Defining the potency of amikacin against , and derived from Chinese hospitals using CLSI and inhalation-based breakpoints. <i>Infection and Drug Resistance</i> , 2018 , 11, 783-790	4.2	11
205	Efficacy of Plazomicin Alone or in Combination with Meropenem or Tigecycline against Enterobacteriaceae Isolates Exhibiting Various Resistance Mechanisms in an Immunocompetent Murine Septicemia Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	14
204	Assessment of the Activity of SPR741 in Combination with Azithromycin against Multidrug-Resistant Enterobacteriaceae Isolates in the Neutropenic Murine Thigh Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	14
203	Management of Pediatric Acute Hematogenous Osteomyelitis, Part I: Antimicrobial Stewardship Approach and Review of Therapies for Methicillin-Susceptible Staphylococcus aureus, Streptococcus pyogenes, and Kingella kingae. <i>Pharmacotherapy</i> , 2018 , 38, 947-966	5.8	11
202	Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Novel Therapy for Multidrug Resistant Gram Negative Infections in Children. <i>Current Pediatric Reviews</i> , 2018 , 14, 97-109	2.8	10
201	Comparative Assessment of Tedizolid Pharmacokinetics and Tissue Penetration between Diabetic Patients with Wound Infections and Healthy Volunteers via Microdialysis. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	11
200	Use of ceftolozane-tazobactam in a cystic fibrosis patient with multidrug-resistant pseudomonas infection and renal insufficiency. <i>Respiratory Medicine Case Reports</i> , 2018 , 23, 8-9	1.2	19
199	1336. Assessment of the In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) Against Carbapenems-Resistant Acinetobacter baumannii (CR-ACBN) in the Neutropenic Murine Thigh Infection Model. <i>Open Forum Infectious Diseases</i> , 2018 , 5, S408-S408	1	1
198	1368. Assessment of the In Vivo Efficacy of Human-Simulated Epithelial Lining Fluid (ELF) Exposure of Meropenem/Nacubactam (MEM/NAC) Combination Against β -Lactamase-Producing Enterobacteriaceae in Neutropenic Lung Infection Model. <i>Open Forum Infectious Diseases</i> , 2018 , 5, S419-S419	1	1
197	1397. Comparative Efficacy of Human-Simulated Epithelial Lining Fluid (ELF) Exposures of Tedizolid (TZD) Against Methicillin-resistant Staphylococcus Aureus (MRSA) in Neutropenic (I) vs. Immunocompetent (I+) Murine Models of Pneumonia. <i>Open Forum Infectious Diseases</i> , 2018 , 5, S430-S430	1	78
196	1405. Efficacy of the Human-Simulated Regimen (HSR) of Cefepime (FEP)/VNRX-5133 Combination Against Serine β -Lactamase-Producing Gram-negative Bacteria in the Neutropenic Murine Thigh Infection Model. <i>Open Forum Infectious Diseases</i> , 2018 , 5, S432-S433	1	3
195	2175. In vitro Potency of Ceftolozane/Tazobactam and Other Antipseudomonal β -Lactams Against P. aeruginosa. <i>Open Forum Infectious Diseases</i> , 2018 , 5, S642-S642	1	78
194	Patient preferences for treatment of acute bacterial skin and skin structure infections in the emergency department. <i>BMC Health Services Research</i> , 2018 , 18, 932	2.9	9
193	Variability in Emergency Medicine Provider Decisions on Hospital Admission and Antibiotic Treatment in a Survey Study for Acute Bacterial Skin and Skin Structure Infections: Opportunities for Antimicrobial Stewardship Education. <i>Open Forum Infectious Diseases</i> , 2018 , 5, ofy206	1	2
192	2176. Single β -Lactams v. Combination Regimens: Assessing the Probability that an Active Agent Would be Selected When Considering Empiric Therapy for P. aeruginosa. <i>Open Forum Infectious Diseases</i> , 2018 , 5, S642-S643	1	78
191	2388. Efficacy of Humanized Cefiderocol Exposures Over 72 Hours Against a Diverse Group of Gram-Negative Isolates in the Neutropenic Murine Thigh Infection Model. <i>Open Forum Infectious Diseases</i> , 2018 , 5, S712-S712	1	78
190	Optimizing Antibiotic Administration for Pneumonia. <i>Clinics in Chest Medicine</i> , 2018 , 39, 837-852	5.3	1
189	Epidemiology of Bloodstream Infections Caused by and That Are Piperacillin-Tazobactam-Nonsusceptible but Ceftriaxone-Susceptible. <i>Open Forum Infectious Diseases</i> , 2018 , 5, ofy300	1	9

188	In Vitro Activity of Newer and Conventional Antimicrobial Agents, Including Fosfomycin and Colistin, against Selected Gram-Negative Bacilli in Kuwait. <i>Pathogens</i> , 2018 , 7,	4.5	8
187	Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. <i>American Journal of Health-System Pharmacy</i> , 2018 , 75, e36-e44	2.2	7
186	Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. <i>American Journal of Health-System Pharmacy</i> , 2018 , 75, 1048-1056	2.2	6
185	Assessment of the Efficacy of WCK 5222 (Cefepime-Zidebactam) against Carbapenem-Resistant <i>Acinetobacter baumannii</i> in the Neutropenic Murine Lung Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	28
184	Pharmacodynamic Target Attainment for Cefepime, Meropenem, and Piperacillin-Tazobactam Using a Pharmacokinetic/Pharmacodynamic-Based Dosing Calculator in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	18
183	Detection of Piperacillin-Tazobactam-Resistant/Pan- β -Lactam-Susceptible <i>Escherichia coli</i> with Current Automated Susceptibility Test Systems. <i>Infection Control and Hospital Epidemiology</i> , 2017 , 38, 379-380	2	4
182	Epidemiology, treatment, and economics of patients presenting to the emergency department for skin and soft tissue infections. <i>Hospital Practice (1995)</i> , 2017 , 45, 9-15	2.2	16
181	The intensive care medicine research agenda on multidrug-resistant bacteria, antibiotics, and stewardship. <i>Intensive Care Medicine</i> , 2017 , 43, 1187-1197	14.5	66
180	Anti-staphylococcal activity resulting from epithelial lining fluid (ELF) concentrations of amikacin inhale administered via the pulmonary drug delivery system. <i>Annals of Clinical Microbiology and Antimicrobials</i> , 2017 , 16, 2	6.2	4
179	Obesity and skin and soft tissue infections: how to optimize antimicrobial usage for prevention and treatment?. <i>Current Opinion in Infectious Diseases</i> , 2017 , 30, 180-191	5.4	12
178	Predicting and preventing antimicrobial resistance utilizing pharmacodynamics: part II Gram-negative bacteria. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017 , 13, 705-714	5.5	8
177	In vitro Activity of Ceftolozane/Tazobactam Alone or with an Aminoglycoside Against Multi-Drug-Resistant <i>Pseudomonas aeruginosa</i> from Pediatric Cystic Fibrosis Patients. <i>Infectious Diseases and Therapy</i> , 2017 , 6, 129-136	6.2	15
176	Population Pharmacokinetics of Cefazolin in Serum and Adipose Tissue From Overweight and Obese Women Undergoing Cesarean Delivery. <i>Journal of Clinical Pharmacology</i> , 2017 , 57, 712-719	2.9	19
175	Physical compatibility of ceftolozane-tazobactam with selected i.v. drugs during simulated Y-site administration. <i>American Journal of Health-System Pharmacy</i> , 2017 , 74, e47-e54	2.2	2
174	Comparative In Vivo Efficacies of Tedizolid in Neutropenic versus Immunocompetent Murine <i>Streptococcus pneumoniae</i> Lung Infection Models. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	13
173	Physical compatibility of isavuconazonium sulfate with select i.v. drugs during simulated Y-site administration. <i>American Journal of Health-System Pharmacy</i> , 2017 , 74, e55-e63	2.2	1
172	Effects of Clinically Meaningful Concentrations of Antipseudomonal β -Lactams on Time to Detection and Organism Growth in Blood Culture Bottles. <i>Journal of Clinical Microbiology</i> , 2017 , 55, 3502-3512 ⁶	2.7	6
171	In Vitro Antibacterial Activity of Ceftolozane/Tazobactam (C/T) Alone and in Combination with other Antimicrobial Agents against Multidrug-Resistant (MDR) <i>Pseudomonas aeruginosa</i> (PSA). <i>Open Forum Infectious Diseases</i> , 2017 , 4, S298-S299	1	

170	Potency of parenteral antimicrobials including ceftolozane/tazobactam against nosocomial respiratory tract pathogens: considerations for empiric and directed therapy. <i>Journal of Thoracic Disease</i> , 2017 , 9, 214-221	2.6	8
169	Efficacy of Humanized Exposures of Cefiderocol (S-649266) against a Diverse Population of Gram-Negative Bacteria in a Murine Thigh Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	58
168	Translational Efficacy of Humanized Exposures of Cefepime, Ertapenem, and Levofloxacin against Extended-Spectrum-β-Lactamase-Producing Escherichia coli in a Murine Model of Complicated Urinary Tract Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	5
167	Pharmacokinetics and Tissue Penetration of Ceftolozane-Tazobactam in Diabetic Patients with Lower Limb Infections and Healthy Adult Volunteers. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	11
166	Comparison of Ceftolozane-Tazobactam to Traditional Beta-Lactams and Ceftolozane-Tazobactam as an Alternative to Combination Antimicrobial Therapy for Pseudomonas aeruginosa. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	27
165	Clinical and economic implications of urinary tract infections. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2017 , 17, 377-383	2.2	10
164	Inhaled Antimicrobials for Ventilator-Associated Pneumonia: Practical Aspects. <i>Drugs</i> , 2017 , 77, 1399-1412.1	2	
163	Antibacterial activity of human simulated epithelial lining fluid concentrations of amikacin inhale alone and in combination with meropenem against Acinetobacter baumannii. <i>Infectious Diseases</i> , 2017 , 49, 831-839	3.1	5
162	Simplifying Piperacillin/Tazobactam Dosing: Pharmacodynamics of Utilizing Only 4.5 or 3.375 g Doses for Patients With Normal and Impaired Renal Function. <i>Journal of Pharmacy Practice</i> , 2017 , 30, 593-599	1.3	1
161	Defining the impact of severity of illness on time above the MIC threshold for cefepime in Gram-negative bacteraemia: a 'Goldilocks' window. <i>International Journal of Antimicrobial Agents</i> , 2017 , 50, 487-490	14.3	13
160	Clinical use comparison of a semiautomated PCR with fluorescent ribotyping for typing of Clostridium difficile. <i>Archives of Microbiology</i> , 2017 , 199, 317-323	3	
159	Spatio-temporal Activity of Human-Simulated Exposures of Meropenem (MEM) and Ceftolozane (TOL) on Pseudomonas aeruginosa Biofilms. <i>Open Forum Infectious Diseases</i> , 2017 , 4, S294-S294	1	
158	infection in the elderly: an update on management. <i>Clinical Interventions in Aging</i> , 2017 , 12, 1799-1809	4	40
157	Cefazolin potency against methicillin-resistant : a microbiologic assessment in support of a novel drug delivery system for skin and skin structure infections. <i>Infection and Drug Resistance</i> , 2017 , 10, 227-230	4.3	8
156	Pharmacodynamic Target Attainment for Meropenem and Piperacillin/Tazobactam Using a PK/PD-based Dosing Calculator in Critically Ill Patients. <i>Open Forum Infectious Diseases</i> , 2017 , 4, S27-S27 ¹		1
155	Multicenter Evaluation of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Inhibitory Activity against Meropenem-Nonsusceptible Pseudomonas aeruginosa from Blood, Respiratory Tract, and Wounds. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	48
154	Management of Pneumonia in the Pediatric Critical Care Unit: An Area for Antimicrobial Stewardship. <i>Current Pediatric Reviews</i> , 2017 , 13, 49-66	2.8	5
153	Isolation and quantitation of Clostridium difficile in aqueous and fecal matter using two types of selective media. <i>Journal of Microbiology, Immunology and Infection</i> , 2016 , 49, 445-7	8.5	5

152	Population pharmacokinetics of meropenem administered as a prolonged infusion in children with cystic fibrosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 189-95	5.1	15
151	Eravacycline Pharmacokinetics and Challenges in Defining Humanized Exposure In Vivo. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 5072-5	5.9	21
150	Population Pharmacokinetics and Safety of Ceftolozane-Tazobactam in Adult Cystic Fibrosis Patients Admitted with Acute Pulmonary Exacerbation. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 6578-6584	5.9	31
149	Treatment of multidrug-resistant <i>Pseudomonas aeruginosa</i> with ceftolozane/tazobactam in a critically ill patient receiving continuous venovenous haemodiafiltration. <i>International Journal of Antimicrobial Agents</i> , 2016 , 48, 342-3	14.3	31
148	Clinical pathway for moderate to severe acute bacterial skin and skin structure infections from a US perspective: a roundtable discussion. <i>Hospital Practice (1995)</i> , 2016 , 44, 183-189	2.2	9
147	Continuous and Prolonged Intravenous β -Lactam Dosing: Implications for the Clinical Laboratory. <i>Clinical Microbiology Reviews</i> , 2016 , 29, 759-72	34	32
146	Pharmacodynamic and pharmacokinetic profiling of delafloxacin in a murine lung model against community-acquired respiratory tract pathogens. <i>International Journal of Antimicrobial Agents</i> , 2016 , 48, 535-541	14.3	32
145	Physical compatibility of tedizolid phosphate with selected i.v. drugs during simulated Y-site administration. <i>American Journal of Health-System Pharmacy</i> , 2016 , 73, 1769-1776	2.2	5
144	Pharmacodynamics of carbapenems for the treatment of <i>Pseudomonas aeruginosa</i> ventilator-associated pneumonia: associations with clinical outcome and recurrence. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 2534-7	5.1	16
143	Transitions of care in the management of acute bacterial skin and skin structure infections: a paradigm shift. <i>Expert Review of Clinical Pharmacology</i> , 2016 , 9, 1039-45	3.8	14
142	In vivo efficacy of humanized high dose meropenem and comparators against <i>Pseudomonas aeruginosa</i> isolates producing verona integron-encoded metallo- β -lactamase (VIM). <i>Heliyon</i> , 2016 , 2, e00121	3.6	1
141	A pilot study to assess bacterial and toxin reduction in patients with <i>Clostridium difficile</i> infection given fidaxomicin or vancomycin. <i>Annals of Clinical Microbiology and Antimicrobials</i> , 2016 , 15, 22	6.2	9
140	Antibacterial Efficacy of Eravacycline In Vivo against Gram-Positive and Gram-Negative Organisms. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 5001-5	5.9	30
139	Predicting and preventing antimicrobial resistance utilizing pharmacodynamics: Part I gram positive bacteria. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016 , 12, 267-80	5.5	12
138	Antibacterial activity of achievable epithelial lining fluid exposures of Amikacin Inhale with or without meropenem. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 428-37	5.1	13
137	Poor outcomes of empiric ceftriaxone+azithromycin for community-acquired pneumonia caused by methicillin-susceptible <i>Staphylococcus aureus</i> . <i>Internal and Emergency Medicine</i> , 2016 , 11, 545-51	3.7	5
136	Effect of Body Weight on Cefazolin and Vancomycin Trabecular Bone Concentrations in Patients Undergoing Total Joint Arthroplasty. <i>Surgical Infections</i> , 2016 , 17, 71-7	2	9
135	In Vitro Pharmacodynamics of Human Simulated Exposures of Telavancin against Methicillin-Susceptible and -Resistant <i>Staphylococcus aureus</i> with and without Prior Vancomycin Exposure. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 222-8	5.9	1

134	Use of Oritavancin in Acute Bacterial Skin and Skin Structure Infections Patients Receiving Intravenous Antibiotics: A US Hospital Budget Impact Analysis. <i>Clinical Drug Investigation</i> , 2016 , 36, 157-68	3.2	14
133	Tissue penetration and exposure of cefepime in patients with diabetic foot infections. <i>International Journal of Antimicrobial Agents</i> , 2016 , 47, 247-8	14.3	3
132	An exploratory analysis of the ability of a cefepime trough concentration greater than 22 mg/L to predict neurotoxicity. <i>Journal of Infection and Chemotherapy</i> , 2016 , 22, 78-83	2.2	19
131	Epidemiology and economics of adult patients hospitalized with urinary tract infections. <i>Hospital Practice (1995)</i> , 2016 , 44, 33-40	2.2	17
130	Optimizing Antibiotic Dosing Strategies for the Treatment of Gram-negative Infections in the Era of Resistance. <i>Expert Review of Clinical Pharmacology</i> , 2016 , 9, 459-76	3.8	21
129	Clinafloxacin for Treatment of Burkholderia cenocepacia Infection in a Cystic Fibrosis Patient. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 1-5	5.9	9
128	Stability of Ertapenem 100 mg/mL at Room Temperature. <i>Canadian Journal of Hospital Pharmacy</i> , 2016 , 69, 256-9	0.5	1
127	Use of Oritavancin in Moderate-to-Severe ABSSSI Patients Requiring IV Antibiotics: A U.S. Payer Budget Impact Analysis. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2016 , 22, 752-64	1.9	12
126	An exploratory study to evaluate Clostridium difficile polymerase chain reaction ribotypes and infection outcomes. <i>Infection and Drug Resistance</i> , 2016 , 9, 143-8	4.2	4
125	Application of "Precision Medicine" Through the Molecular Characterization of Extensively Drug Resistant (XDR) Klebsiella pneumoniae in a Multivisceral Transplant Candidate. <i>Open Forum Infectious Diseases</i> , 2016 , 3,	1	1
124	Ceftolozane/tazobactam and ceftazidime/avibactam for the treatment of complicated intra-abdominal infections. <i>Therapeutics and Clinical Risk Management</i> , 2016 , 12, 1811-1826	2.9	23
123	Ceftolozane/Tazobactam Pharmacokinetics in a Critically Ill Adult Receiving Continuous Renal Replacement Therapy. <i>Pharmacotherapy</i> , 2016 , 36, e30-e33	5.8	35
122	In vitro potency of amikacin and comparators against E. coli, K. pneumoniae and P. aeruginosa respiratory and blood isolates. <i>Annals of Clinical Microbiology and Antimicrobials</i> , 2016 , 15, 39	6.2	18
121	Successful Treatment of Multi-Drug Resistant Pseudomonas aeruginosa Bacteremia with the Recommended Renally Adjusted Ceftolozane/Tazobactam Regimen. <i>Infectious Diseases and Therapy</i> , 2016 , 5, 73-9	6.2	20
120	Assessment of Clostridium difficile Burden in Patients Over Time With First Episode Infection Following Fidaxomicin or Vancomycin. <i>Infection Control and Hospital Epidemiology</i> , 2016 , 37, 215-8	2	14
119	Antibiotic Utilization and Opportunities for Stewardship Among Hospitalized Patients With Influenza Respiratory Tract Infection. <i>Infection Control and Hospital Epidemiology</i> , 2016 , 37, 583-9	2	19
118	Can we improve clinical outcomes in patients with pneumonia treated with antibiotics in the intensive care unit?. <i>Expert Review of Respiratory Medicine</i> , 2016 , 10, 907-18	3.8	10
117	Evaluation of a disease state management guideline for urinary tract infection. <i>International Journal of Antimicrobial Agents</i> , 2016 , 47, 451-6	14.3	4

116	Development of an HPLC Method for the Determination of Ceftolozane/Tazobactam in Biological and Aqueous Matrixes. <i>Journal of Chromatographic Science</i> , 2016 , 54, 1037-40	1.4	27
115	In Vitro Pharmacodynamics of Vancomycin against Methicillin-Susceptible and -Resistant <i>Staphylococcus aureus</i> : Considering the Variability in Observed Tissue Exposure. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 955-61	5.9	5
114	Characteristics of an ideal nebulized antibiotic for the treatment of pneumonia in the intubated patient. <i>Annals of Intensive Care</i> , 2016 , 6, 35	8.9	47
113	Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Infection in a Child with Cystic Fibrosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 5627-30	5.9	17
112	Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia. <i>Journal of Clinical Pharmacology</i> , 2016 , 56, 56-66	2.9	114
111	In vivo activities of simulated human doses of cefepime and cefepime-AA1101 against multidrug-resistant Gram-negative Enterobacteriaceae. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 2688-94	5.9	41
110	Susceptibility Profile of Ceftolozane/Tazobactam and Other Parenteral Antimicrobials Against <i>Escherichia coli</i> , <i>Klebsiella pneumoniae</i> , and <i>Pseudomonas aeruginosa</i> From US Hospitals. <i>Clinical Therapeutics</i> , 2015 , 37, 1564-71	3.5	43
109	Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 2862-9	5.1	75
108	Effects of Urine Matrix and pH on the Potency of Delafloxacin and Ciprofloxacin against Urogenic <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> . <i>Journal of Urology</i> , 2015 , 194, 563-70	2.5	24
107	Increased 3-gram ceftazidime dosing for cesarean delivery prophylaxis in obese women. <i>American Journal of Obstetrics and Gynecology</i> , 2015 , 213, 415.e1-8	6.4	98
106	Focus on ceftazidime-avibactam for optimizing outcomes in complicated intra-abdominal and urinary tract infections. <i>Expert Opinion on Investigational Drugs</i> , 2015 , 24, 1261-73	5.9	8
105	Discovery and Characterization of a Water-Soluble Prodrug of a Dual Inhibitor of Bacterial DNA Gyrase and Topoisomerase IV. <i>ACS Medicinal Chemistry Letters</i> , 2015 , 6, 822-6	4.3	16
104	Presence of infection influences the epithelial lining fluid penetration of oral levofloxacin in adult patients. <i>International Journal of Antimicrobial Agents</i> , 2015 , 45, 512-8	14.3	6
103	Impact of revised cefepime CLSI breakpoints on <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> susceptibility and potential impact if applied to <i>Pseudomonas aeruginosa</i> . <i>Journal of Clinical Microbiology</i> , 2015 , 53, 1712-4	9.7	11
102	Microbiological activity of ceftolozane/tazobactam, ceftazidime, meropenem, and piperacillin/tazobactam against <i>Pseudomonas aeruginosa</i> isolated from children with cystic fibrosis. <i>Diagnostic Microbiology and Infectious Disease</i> , 2015 , 83, 53-5	2.9	31
101	Vancomycin serum concentrations do not adequately predict tissue exposure in diabetic patients with mild to moderate limb infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 2064-7	5.1	14
100	Pharmacodynamic Profiling of a Siderophore-Conjugated Monocarbam in <i>Pseudomonas aeruginosa</i> : Assessing the Risk for Resistance and Attenuated Efficacy. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 7743-52	5.9	52
99	Efficacy of humanized high-dose meropenem, cefepime, and levofloxacin against Enterobacteriaceae isolates producing Verona integron-encoded metallo- β -lactamase (VIM) in a murine thigh infection model. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 7145-7	5.9	14

98	Impact of vancomycin faecal concentrations on clinical and microbiological outcomes in <i>Clostridium difficile</i> infection. <i>International Journal of Antimicrobial Agents</i> , 2015 , 46, 205-8	14.3	12
97	Demography and burden of care associated with patients readmitted for urinary tract infection. <i>Journal of Microbiology, Immunology and Infection</i> , 2015 , 48, 517-24	8.5	3
96	Defining Clinical Exposures of Cefepime for Gram-Negative Bloodstream Infections That Are Associated with Improved Survival. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 60, 1401-10	5.9	35
95	Ceftolozane-Tazobactam Pharmacokinetics in a Critically Ill Patient on Continuous Venovenous Hemofiltration. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 60, 1899-901	5.9	32
94	Lack of Correlation between Bristol Stool Scale and Quantitative Bacterial Load in <i>Clostridium difficile</i> Infection. <i>Infectious Diseases: Research and Treatment</i> , 2015 , 8, 1-4	3.1	5
93	Making a Case for Pediatric Antimicrobial Stewardship Programs. <i>Pharmacotherapy</i> , 2015 , 35, 1026-36	5.8	22
92	Impact of the New Delhi metallo-beta-lactamase on beta-lactam antibiotics. <i>Infection and Drug Resistance</i> , 2015 , 8, 297-309	4.2	37
91	Assessing the Surrogate Susceptibility of Oxacillin and Cefoxitin for Commonly Utilized Parenteral Agents against Methicillin-Susceptible <i>Staphylococcus aureus</i> : Focus on Ceftriaxone Discordance between Predictive Susceptibility and in Vivo Exposures. <i>Pathogens</i> , 2015 , 4, 599-605	4.5	6
90	In Vitro Activity of Cefepime/AAI101 and Comparators against Cefepime Non-susceptible Enterobacteriaceae. <i>Pathogens</i> , 2015 , 4, 620-5	4.5	27
89	Potential of antibacterial activity of the MB-1 siderophore-monobactam conjugate using an efflux pump inhibitor. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 2439-42	5.9	26
88	Pharmacodynamic Profile of GSK2140944 against Methicillin-Resistant <i>Staphylococcus aureus</i> in a Murine Lung Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 4956-61	5.9	17
87	Validation of a Dosing Strategy for Cefazolin for Surgery Requiring Cardiopulmonary Bypass. <i>Surgical Infections</i> , 2015 , 16, 829-32	2	4
86	Defining Extended Spectrum β -Lactamases: Implications of Minimum Inhibitory Concentration-Based Screening Versus Clavulanate Confirmation Testing. <i>Infectious Diseases and Therapy</i> , 2015 , 4, 513	6.2	1
85	Humanized tissue pharmacodynamics of cefazolin against commonly isolated pathogens in skin and skin structure infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 2443-7	5.1	4
84	Prolonging β -Lactam infusion: a review of the rationale and evidence, and guidance for implementation. <i>International Journal of Antimicrobial Agents</i> , 2014 , 43, 105-13	14.3	49
83	In vitro pharmacodynamics of polymyxin B and tigecycline alone and in combination against carbapenem-resistant <i>Acinetobacter baumannii</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 874-9	5.9	52
82	Supporting the ceftaroline fosamil/avibactam Enterobacteriaceae breakpoint determination using humanised in vivo exposures in a thigh model. <i>International Journal of Antimicrobial Agents</i> , 2014 , 44, 508-13	14.3	1
81	To add or not to add polysorbate 80: impact on colistin MICs for clinical strains of Enterobacteriaceae and <i>Pseudomonas aeruginosa</i> and quality controls. <i>Journal of Clinical Microbiology</i> , 2014 , 52, 3810	9.7	15

80	Pharmacodynamic profile of commonly utilised parenteral therapies against meticillin-susceptible and meticillin-resistant <i>Staphylococcus aureus</i> collected from US hospitals. <i>International Journal of Antimicrobial Agents</i> , 2014 , 44, 235-41	14.3	31
79	In vitro activity of human-simulated epithelial lining fluid exposures of ceftaroline, ceftriaxone, and vancomycin against methicillin-susceptible and -resistant <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 7520-6	5.9	15
78	Pharmacodynamic profiling of modithromycin: assessment in a pneumococcal murine pneumonia model. <i>International Journal of Antimicrobial Agents</i> , 2014 , 43, 540-6	14.3	2
77	Efficacies of ceftazidime-avibactam and ceftazidime against <i>Pseudomonas aeruginosa</i> in a murine lung infection model. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 1365-71	5.9	47
76	In vitro microdialysis membrane efficiency of broad-spectrum antibiotics in combination and alone. <i>Clinical Pharmacology: Advances and Applications</i> , 2014 , 6, 97-101	1.5	3
75	In vivo efficacy of humanized exposures of Ceftazidime-Avibactam in comparison with Ceftazidime against contemporary Enterobacteriaceae isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 6913-9	5.9	31
74	Population Pharmacokinetics of Cefazolin in Serum and Tissue for Patients with Complicated Skin and Soft Tissue Infections (cSSTI). <i>Infectious Diseases and Therapy</i> , 2014 , 3, 269-79	6.2	10
73	Clinical pharmacodynamics of antipseudomonal cephalosporins in patients with ventilator-associated pneumonia. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 1359-64	5.9	55
72	Unexpected in vivo activity of ceftazidime alone and in combination with avibactam against New Delhi metallo- β -lactamase-producing Enterobacteriaceae in a murine thigh infection model. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 7007-9	5.9	28
71	Comparison of in vivo and in vitro pharmacodynamics of a humanized regimen of 600 milligrams of Ceftaroline Fosamil every 12 hours against <i>Staphylococcus aureus</i> at initial inocula of 106 and 108 CFU per milliliter. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 6931-3	5.9	9
70	In vivo efficacy of human simulated regimens of carbapenems and comparator agents against NDM-1-producing Enterobacteriaceae. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 1671-7	5.9	29
69	Stability of ertapenem 100 mg/mL in polypropylene syringes stored at 25, 4, and -20 °C. <i>American Journal of Health-System Pharmacy</i> , 2014 , 71, 1480-4	2.2	5
68	Successful application of serum shift prediction models to the design of dual targeting inhibitors of bacterial gyrase B and topoisomerase IV with improved in vivo efficacy. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014 , 24, 2177-81	2.9	8
67	Pharmacokinetics of intravenous linezolid in moderately to morbidly obese adults. <i>Antimicrobial Agents and Chemotherapy</i> , 2013 , 57, 1144-9	5.9	50
66	Human simulated studies of aztreonam and aztreonam-avibactam to evaluate activity against challenging gram-negative organisms, including metallo- β -lactamase producers. <i>Antimicrobial Agents and Chemotherapy</i> , 2013 , 57, 3299-306	5.9	85
65	Efficacy of humanized carbapenem exposures against New Delhi metallo- β -lactamase (NDM-1)-producing enterobacteriaceae in a murine infection model. <i>Antimicrobial Agents and Chemotherapy</i> , 2013 , 57, 3936-40	5.9	29
64	Cefepime dosing in the morbidly obese patient population. <i>Obesity Surgery</i> , 2012 , 22, 465-71	3.7	27
63	Bronchopulmonary pharmacokinetic and pharmacodynamic profiles of levofloxacin 750mg once daily in adults undergoing treatment for acute exacerbation of chronic bronchitis. <i>Pulmonary Pharmacology and Therapeutics</i> , 2012 , 25, 94-8	3.5	14

62	Carbapenem stewardship: does ertapenem affect Pseudomonas susceptibility to other carbapenems? A review of the evidence. <i>International Journal of Antimicrobial Agents</i> , 2012 , 39, 11-5	14.3	47
61	Reply to Double-Carbapenem Therapy Not Proven To Be More Active than Carbapenem Monotherapy against KPC-Positive Klebsiella pneumoniae. <i>Antimicrobial Agents and Chemotherapy</i> , 2012 , 56, 4038-4038	5.9	2
60	Current challenges in the management of the infected patient. <i>Current Opinion in Infectious Diseases</i> , 2011 , 24 Suppl 1, S1-10	5.4	26
59	Optimization of meropenem dosage in the critically ill population based on renal function. <i>Intensive Care Medicine</i> , 2011 , 37, 632-8	14.5	69
58	In vivo efficacy of a human-simulated regimen of ceftaroline combined with NXL104 against extended-spectrum-beta-lactamase (ESBL)-producing and non-ESBL-producing Enterobacteriaceae. <i>Antimicrobial Agents and Chemotherapy</i> , 2011 , 55, 3220-5	5.9	50
57	Clinical pharmacodynamics of cefepime in patients infected with Pseudomonas aeruginosa. <i>Antimicrobial Agents and Chemotherapy</i> , 2010 , 54, 1111-6	5.9	89
56	Therapeutic options for diabetic foot infections: a review with an emphasis on tissue penetration characteristics. <i>Journal of the American Podiatric Medical Association</i> , 2010 , 100, 52-63	1	29
55	Pharmacodynamics and tolerability of high-dose, prolonged infusion carbapenems in adults with cystic fibrosis [A review of 3 cases. <i>Respiratory Medicine CME</i> , 2010 , 3, 146-149		12
54	Pharmacotherapy of Complicated Urinary Tract and Intra-abdominal Infections with Doripenem. <i>Clinical Medicine Therapeutics</i> , 2009 , 1, CMT.S2062		
53	Management of complicated infections in the era of antimicrobial resistance: the role of tigecycline. <i>Expert Opinion on Pharmacotherapy</i> , 2009 , 10, 1213-22	4	24
52	Population pharmacokinetics of high-dose, prolonged-infusion cefepime in adult critically ill patients with ventilator-associated pneumonia. <i>Antimicrobial Agents and Chemotherapy</i> , 2009 , 53, 1476-81	5.9	89
51	What is the 360-degree approach to defining success for VAP?. <i>Journal of Managed Care Pharmacy</i> , 2009 , 15, S3-4		
50	Carbapenems: a potent class of antibiotics. <i>Expert Opinion on Pharmacotherapy</i> , 2008 , 9, 23-37	4	114
49	Pharmacodynamic optimization of beta-lactams in the patient care setting. <i>Critical Care</i> , 2008 , 12 Suppl 4, S2	10.8	38
48	Bugs versus drugs: what is the pharmacist's challenge?. <i>American Journal of Health-System Pharmacy</i> , 2008 , 65, S2-3	2.2	1
47	Influence of automated screening and confirmation of extended-spectrum beta-lactamase-producing members of the Enterobacteriaceae on prescribing of antibiotics. <i>Journal of Medical Microbiology</i> , 2008 , 57, 1147-1151	3.2	
46	Pharmacokinetic and pharmacodynamic properties of meropenem. <i>Clinical Infectious Diseases</i> , 2008 , 47 Suppl 1, S32-40	11.6	132
45	Pharmacodynamic target attainment of seven antimicrobials against Gram-negative bacteria collected from China in 2003 and 2004. <i>International Journal of Antimicrobial Agents</i> , 2007 , 30, 452-7	14.3	25

44	Employing pharmacokinetic and pharmacodynamic principles to optimize antimicrobial treatment in the face of emerging resistance. <i>Brazilian Journal of Microbiology</i> , 2007 , 38, 183-193	2.2	8
43	Cefepime pharmacodynamics in patients with extended spectrum beta-lactamase (ESBL) and non-ESBL infections. <i>Journal of Infection</i> , 2007 , 54, 463-8	18.9	40
42	Pharmacokinetics of dalbavancin in plasma and skin blister fluid. <i>Journal of Antimicrobial Chemotherapy</i> , 2007 , 60, 681-4	5.1	51
41	Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2007 , 51, 1725-30	5.9	208
40	Treatment of <i>Serratia marcescens</i> meningitis with prolonged infusion of meropenem. <i>Annals of Pharmacotherapy</i> , 2007 , 41, 1077-81	2.9	20
39	Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> in a neutropenic mouse thigh model. <i>Antimicrobial Agents and Chemotherapy</i> , 2007 , 51, 1481-6	5.9	48
38	Empiric therapy for secondary peritonitis: a pharmacodynamic analysis of cefepime, ceftazidime, ceftriaxone, imipenem, levofloxacin, piperacillin/tazobactam, and tigecycline using Monte Carlo simulation. <i>Clinical Therapeutics</i> , 2007 , 29, 889-899	3.5	12
37	Comparative in vivo efficacy of meropenem, imipenem, and cefepime against <i>Pseudomonas aeruginosa</i> expressing MexA-MexB-OprM efflux pumps. <i>Diagnostic Microbiology and Infectious Disease</i> , 2007 , 57, 153-61	2.9	44
36	Pharmacokinetics of cefprozil in plasma and middle ear fluid: in children undergoing treatment for acute otitis media. <i>Paediatric Drugs</i> , 2007 , 9, 119-23	4.2	9
35	Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients. <i>Journal of Clinical Pharmacology</i> , 2006 , 46, 1171-8	2.9	118
34	Comparison of clarithromycin and ciprofloxacin therapy for <i>Bacillus anthracis</i> Sterne infection in mice with or without (60)Co gamma-photon irradiation. <i>Journal of Medical Microbiology</i> , 2005 , 54, 1157-1162	3.2	4
33	Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2005 , 56, 388-95	5.1	81
32	Pharmacodynamics of antimicrobials: treatment optimisation. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2005 , 1, 351-61	5.5	18
31	IV to Oral Conversion Programs for Anti-Infectives in the United States: Prevalence and Characteristics. <i>Hospital Pharmacy</i> , 2004 , 39, 1069-1075	1.1	1
30	Clinical use of antimicrobial pharmacodynamic profiles to optimise treatment outcomes in community-acquired bacterial respiratory tract infections: application to telithromycin. <i>Expert Opinion on Pharmacotherapy</i> , 2004 , 5, 229-35	4	8
29	Empiric treatment of multidrug-resistant <i>Burkholderia cepacia</i> lung exacerbation in a patient with cystic fibrosis: application of pharmacodynamic concepts to meropenem therapy. <i>Pharmacotherapy</i> , 2004 , 24, 1641-5	5.8	30
28	Meropenem administered as a prolonged infusion to treat serious gram-negative central nervous system infections. <i>Pharmacotherapy</i> , 2004 , 24, 803-7	5.8	23
27	Optimizing Efficacy in CARTIs: introduction. <i>Annals of Pharmacotherapy</i> , 2004 , 38, S7	2.9	

26	Treatment with appropriate antibiotic therapy in community-acquired respiratory tract infections. <i>American Journal of Managed Care</i> , 2004 , 10, S381-8	2.1	3
25	Pharmacodynamics of a novel des-F(6)-quinolone, BMS-284756, against <i>Streptococcus pneumoniae</i> in the thigh infection model. <i>Antimicrobial Agents and Chemotherapy</i> , 2003 , 47, 1630-5	5.9	14
24	Economic benefit of a meropenem dosage strategy based on pharmacodynamic concepts. <i>American Journal of Health-System Pharmacy</i> , 2003 , 60, 565-8	2.2	29
23	Optimizing outcomes with antimicrobial therapy through pharmacodynamic profiling. <i>Journal of Infection and Chemotherapy</i> , 2003 , 9, 292-6	2.2	63
22	Influence of sex on the pharmacokinetic interaction of fleroxacin and ciprofloxacin with caffeine. <i>Clinical Pharmacokinetics</i> , 2003 , 42, 985-96	6.2	9
21	Maximizing outcomes in respiratory tract infections in the age of resistance. <i>Pharmacotherapy</i> , 2002 , 22, 1S; discussion 30S-32S	5.8	1
20	Pharmacokinetic and pharmacodynamic evaluation of two dosing regimens for piperacillin-tazobactam. <i>Pharmacotherapy</i> , 2002 , 22, 569-77	5.8	34
19	Clinical and economic implications of antimicrobial resistance for the management of community-acquired respiratory tract infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2002 , 50 Suppl S1, 61-70	5.1	36
18	Antibacterials for the prophylaxis and treatment of bacterial endocarditis in children. <i>Paediatric Drugs</i> , 2001 , 3, 703-18	4.2	4
17	Pharmacodynamic assessment of cefprozil against <i>Streptococcus pneumoniae</i> : implications for breakpoint determinations. <i>Antimicrobial Agents and Chemotherapy</i> , 2000 , 44, 1291-5	5.9	33
16	Pharmacokinetics of ticlopidine in the rabbit. <i>Journal of Pharmacy and Pharmacology</i> , 1999 , 51, 393-6	4.8	2
15	Population pharmacokinetics of continuous infusion ceftazidime. <i>Clinical Pharmacokinetics</i> , 1999 , 37, 343-50	6.2	13
14	Pharmacokinetics and Pharmacodynamics of Continuous and Intermittent Ceftazidime during the Treatment of Nosocomial Pneumonia. <i>Clinical Drug Investigation</i> , 1999 , 18, 133-139	3.2	16
13	Use of a bioabsorbable polymer for the delivery of ofloxacin during experimental osteomyelitis treatment. <i>Journal of Orthopaedic Research</i> , 1998 , 16, 76-9	3.8	34
12	Infusion phlebitis: relative incidence associated with cefuroxime administered by intermittent and continuous infusion. <i>Clinical Drug Investigation</i> , 1998 , 15, 531-5	3.2	2
11	Cost comparison of single daily i.v. doses of ceftriaxone versus continuous infusion of cefotaxime. <i>American Journal of Health-System Pharmacy</i> , 1997 , 54, 1614-8	2.2	18
10	Pharmacoeconomics of <i>Pneumocystis carinii</i> pneumonia in HIV-infected and HIV-noninfected patients. <i>Pharmacoeconomics</i> , 1996 , 10, 72-8	4.4	5
9	Activities of clarithromycin, azithromycin, and ofloxacin in combination with liposomal or unencapsulated granulocyte-macrophage colony-stimulating factor against intramacrophage <i>Mycobacterium avium</i> - <i>Mycobacterium intracellulare</i> . <i>Journal of Infectious Diseases</i> , 1995 , 172, 810-6	7	27

8	In vitro elution of ofloxacin from a bioabsorbable polymer. <i>Acta Orthopaedica</i> , 1995 , 66, 365-8		31
7	Clinical pharmacokinetics of newer cephalosporins. <i>Clinical Pharmacokinetics</i> , 1995 , 28, 361-84	6.2	33
6	The effect of fleroxacin and ciprofloxacin on the pharmacokinetics of multiple dose caffeine. <i>Drugs</i> , 1995 , 49 Suppl 2, 357-9	12.1	4
5	Intracellular and Extracellular Penetration of Azithromycin into Inflammatory and Noninflammatory Blister Fluid. <i>Antimicrobial Agents and Chemotherapy</i> , 1995 , 39, 795-795	5.9	78
4	Serum bactericidal activity of ceftriaxone plus metronidazole against common intra-abdominal pathogens. <i>American Journal of Health-System Pharmacy</i> , 1994 , 51, 1782-1787	2.2	
3	Choosing between the new cephalosporin antibiotics: a pharmacodynamic approach. <i>Pharmacoeconomics</i> , 1994 , 5, 34-9	4.4	12
2	Lomefloxacin clinical pharmacokinetics. <i>Clinical Pharmacokinetics</i> , 1993 , 25, 6-19	6.2	10
1	Impact of Order-Set Modifications and Provider Education Following Guideline Updates on Broad-Spectrum Antibiotic Use in Patients Admitted With Community Acquired Pneumonia. <i>Hospital Pharmacy</i> ,001857872110557	1.1	